Are timely access and robust safety mutually exclusive?
pharmaphorum
JULY 6, 2022
And how can regulators balance timely access with robust safety? A new cross-sectional study has found that the FDA green lit 95% of the 89 new oncology therapies approved between 2010 and 2019 before the EMA, with the Europeans trailing the Americans by a median of 241 days. Accelerating safe access. appeared first on.
Let's personalize your content